Precision Biologics develops tumor-specific monoclonal antibodies and companion diagnostics for the treatment of solid-tumor cancers. Precision Biologics is a clinical stage biotechnology company, developing therapeutic and diagnostic products against cancer.
Precision Biologics, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/precision-biologics” connections=”true” suffix=””]
Precision key technology platform rely on the use of proprietary library of cancer vaccines, derived from tumor associated antigens, isolated from cancer of numerous patients in the 1970s and 1980s, and tested in vaccine clinical trials under the guidance of the FDA.
In Sep 2012, Precision Biologics acquired Neogenix Oncology for $2.79 Mn USD and purchased the library of vaccines, antibodies, antigens, and other assets of Neogenix.
In Oct 2015, Precision Biologics received a $50 Mn equity investment from NantWorks, LLC. In turn NantWorks acquires Majority Stake in Precision Biologics.